nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

22.08.2018 | Review – Cancer Research

Role of ferroptosis in hepatocellular carcinoma

verfasst von: Jianhua Nie, Binlin Lin, Meng Zhou, Li Wu, Tongsen Zheng

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 12/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Hepatocellular carcinoma (HCC) is a complicated disease with low survival rate due to frequent recurrence and the lack of efficient therapies. For advanced HCC, sorafenib, as the only approved first-line drug for HCC, improves the survival to some extent, but depressingly with severe adverse effects and emerging resistance conditions, which cause a poor prognosis. Ferroptosis is a new recognized way of non-apoptosis-regulated cell death, characterized by the iron-dependent accumulation of lipid hydroperoxides, showing a tremendous promising in the therapy of cancer, especially in HCC. To provide ideas for the diagnosis and treatment of HCC, we summarized the role of ferroptosis in HCC.

Methods

The relevant literature from PubMed is reviewed in this article.

Results

Interestingly enough, investigators have found sorafenib can induce ferroptosis in HCC. Moreover, recent researches reported increasing pathways and mechanisms related to ferroptosis in HCC such as TP53 and Rb, and strategies to improve sorafenib resistance by targeting ferroptosis. In addition, other drugs were reported to induce ferroptosis in HCC such as erastin and showed good efficacy in vivo and in vitro.

Conclusion

In this review, we summarize pathways and mechanisms of ferroptosis in HCC and other digestive system neoplasms such as gastric cancer, pancreatic cancer and colorectal cancer and point out the trends of ferroptosis in HCC.

Alvarez SW et al (2017) NFS1 undergoes positive selection in lung tumours and protects cells from ferroptosis. Nature 551:639–643. https://doi.org/10.1038/nature24637 CrossRefPubMedPubMedCentral

Arlt A et al (2013) Inhibition of the Nrf2 transcription factor by the alkaloid trigonelline renders pancreatic cancer cells more susceptible to apoptosis through decreased proteasomal gene expression and proteasome activity. Oncogene 32:4825–4835. https://doi.org/10.1038/onc.2012.493 CrossRefPubMed

Bai T, Wang S, Zhao Y, Zhu R, Wang W, Sun Y (2017) Haloperidol, a sigma receptor 1 antagonist, promotes ferroptosis in hepatocellular carcinoma cells. Biochem Biophys Res Commun 491:919–925. https://doi.org/10.1016/j.bbrc.2017.07.136 CrossRefPubMed

Bruix J et al (2017) Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London England) 389:56–66. https://doi.org/10.1016/s0140-6736(16)32453-9 CrossRef

Chen WC, Wang CY, Hung YH, Weng TY, Yen MC, Lai MD (2016) Systematic analysis of gene expression alterations and clinical outcomes for long-chain acyl-coenzyme a synthetase family in cancer. PloS One 11:e0155660. https://doi.org/10.1371/journal.pone.0155660 CrossRefPubMedPubMedCentral

Cheng AL et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25–34. https://doi.org/10.1016/s1470-2045(08)70285-7 CrossRefPubMed

Dixon SJ et al (2012) Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149:1060–1072. https://doi.org/10.1016/j.cell.2012.03.042 CrossRefPubMedPubMedCentral

Dixon SJ et al (2014) Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress ferroptosis. Elife 3:e02523. https://doi.org/10.7554/eLife.02523 CrossRefPubMedPubMedCentral

Do Van B et al (2016) Ferroptosis, a newly characterized form of cell death in Parkinson’s disease that is regulated by PKC. Neurobiol Dis 94:169–178. https://doi.org/10.1016/j.nbd.2016.05.011 CrossRefPubMed

Eling N, Reuter L, Hazin J, Hamacher-Brady A, Brady NR (2015) Identification of artesunate as a specific activator of ferroptosis in pancreatic cancer cells. Oncoscience 2:517–532. https://doi.org/10.18632/oncoscience.160 CrossRefPubMedPubMedCentral

Firestone RA (1994) Low-density lipoprotein as a vehicle for targeting antitumor compounds to cancer cells. Bioconj Chem 5:105–113CrossRefPubMed

Friedmann Angeli JP et al (2014) Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat Cell Biol 16:1180–1191. https://doi.org/10.1038/ncb3064 CrossRefPubMed

Galmiche A, Chauffert B, Barbare JC (2014) New biological perspectives for the improvement of the efficacy of sorafenib in hepatocellular carcinoma. Cancer Lett 346:159–162. https://doi.org/10.1016/j.canlet.2013.12.028 CrossRefPubMed

Guo J et al (2018) Ferroptosis: a novel anti-tumor action for cisplatin. Cancer Res Treat 50:445–460. https://doi.org/10.4143/crt.2016.572 CrossRefPubMed

Hambright WS, Fonseca RS, Chen L, Na R, Ran Q (2017) Ablation of ferroptosis regulator glutathione peroxidase 4 in forebrain neurons promotes cognitive impairment and neurodegeneration. Redox Biol 12:8–17 https://doi.org/10.1016/j.redox.2017.01.021 CrossRefPubMedPubMedCentral

Hao S et al (2017) Cysteine dioxygenase 1 mediates erastin-induced ferroptosis in human gastric cancer cells. Neoplasia (New York NY) 19:1022–1032. https://doi.org/10.1016/j.neo.2017.10.005 CrossRef

Harrison PM, Arosio P (1996) The ferritins: molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta 1275:161–203CrossRefPubMed

Hayano M, Yang WS, Corn CK, Pagano NC, Stockwell BR (2016) Loss of cysteinyl-tRNA synthetase (CARS) induces the transsulfuration pathway and inhibits ferroptosis induced by cystine deprivation. Cell Death Diff 23:270–278. https://doi.org/10.1038/cdd.2015.93 CrossRef

Hayes JD, McLellan LI (1999) Glutathione and glutathione-dependent enzymes represent a co-ordinately regulated defence against oxidative stress. Free Rad Res 31:273–300CrossRef

Hong SH et al (2017) Molecular crosstalk between ferroptosis and apoptosis: emerging role of ER stress-induced p53-independent. PUMA Exp Oncotarget 8:115164–115178. https://doi.org/10.18632/oncotarget.23046 CrossRef

Hou W et al (2016) Autophagy promotes ferroptosis by degradation of ferritin. Autophagy 12:1425–1428. https://doi.org/10.1080/15548627.2016.1187366 CrossRefPubMedPubMedCentral

Hsu C, Shen YC, Cheng AL (2009) Sorafenib for the treatment of hepatocellular carcinoma across geographic regions. Expert Rev Clin Pharmacol 2:129–136. https://doi.org/10.1586/17512433.2.2.129 CrossRefPubMed

Jennis M et al (2016) An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model. Genes Dev 30:918–930 https://doi.org/10.1101/gad.275891.115 CrossRefPubMedPubMedCentral

Kasukabe T, Honma Y, Okabe-Kado J, Higuchi Y, Kato N, Kumakura S (2016) Combined treatment with cotylenin A and phenethyl isothiocyanate induces strong antitumor activity mainly through the induction of ferroptotic cell death in human pancreatic cancer cells. Oncol Rep 36:968–976. https://doi.org/10.3892/or.2016.4867 CrossRefPubMed

Khan MR, Xiang S (2017) The p53-inducible long noncoding RNA TRINGS protects cancer cells from necrosis under glucose starvation. EMBO J 36:3483–3500. https://doi.org/10.15252/embj.201696239 CrossRefPubMedPubMedCentral

Kinowaki Y et al (2018) Glutathione peroxidase 4 overexpression inhibits ROS-induced cell death in diffuse large B-cell lymphoma Laboratory investigation. J Tech Methods Pathol. https://doi.org/10.1038/s41374-017-0008-1 CrossRef

Knudsen ES, Knudsen KE (2008) Tailoring to RB: tumour suppressor status and therapeutic response. Nat Rev Cancer 8:714–724. https://doi.org/10.1038/nrc2401 CrossRefPubMedPubMedCentral

Lachaier E et al (2014) Sorafenib induces ferroptosis in human cancer cell lines originating from different solid tumors. Anticancer Res 34:6417–6422PubMed

Liu L et al (2006) Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66:11851–11858. https://doi.org/10.1158/0008-5472.can-06-1377 CrossRefPubMed

Liu J, Liu Y, Meng L, Liu K, Ji B (2017) Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma. Oncol Rep 38:899–907. https://doi.org/10.3892/or.2017.5722 CrossRefPubMedPubMedCentral

Llovet JM et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390. https://doi.org/10.1056/NEJMoa0708857 CrossRefPubMed

Louandre C, Ezzoukhry Z, Godin C, Barbare JC, Maziere JC, Chauffert B, Galmiche A (2013) Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib. Int J Cancer 133:1732–1742. https://doi.org/10.1002/ijc.28159 CrossRefPubMed

Louandre C et al (2015) The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells. Cancer Lett 356:971–977. https://doi.org/10.1016/j.canlet.2014.11.014 CrossRefPubMed

Ma Q (2013) Role of nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol 53:401–426. https://doi.org/10.1146/annurev-pharmtox-011112-140320 CrossRefPubMedPubMedCentral

Ma S, Henson ES, Chen Y, Gibson SB (2016) Ferroptosis is induced following siramesine and lapatinib treatment of breast cancer cells. Cell Death Dis 7:e2307. https://doi.org/10.1038/cddis.2016.208 CrossRefPubMedPubMedCentral

Mayhew CN et al (2007) RB loss abrogates cell cycle control and genome integrity to promote liver tumorigenesis. Gastroenterology 133:976–984. https://doi.org/10.1053/j.gastro.2007.06.025 CrossRefPubMed

Mrakovcic M, Frohlich LF (2018) p53-mediated molecular control of autophagy in tumor cells. Biomolecules. https://doi.org/10.3390/biom8020014 CrossRefPubMedPubMedCentral

Ou W, Mulik RS, Anwar A, McDonald JG, He X, Corbin IR (2017) Low-density lipoprotein docosahexaenoic acid nanoparticles induce ferroptotic cell death in hepatocellular carcinoma. Free Rad Biol Med 112:597–607. https://doi.org/10.1016/j.freeradbiomed.2017.09.002 CrossRefPubMed

Shi X et al (2014) Nutlin-3 downregulates p53 phosphorylation on serine392 and induces apoptosis in hepatocellular carcinoma cells. BMB Rep 47:221–226CrossRefPubMedPubMedCentral

Shintoku R et al (2017) Lipoxygenase-mediated generation of lipid peroxides enhances ferroptosis induced by erastin and RSL3. Cancer Sci 108:2187–2194 https://doi.org/10.1111/cas.13380 CrossRefPubMedPubMedCentral

Sun X, Niu X, Chen R, He W, Chen D, Kang R, Tang D (2016a) Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis. Hepatology (Baltimore, Md) 64:488–500. https://doi.org/10.1002/hep.28574 CrossRef

Sun X, Ou Z, Chen R, Niu X, Chen D, Kang R, Tang D (2016b) Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology (Baltimore, Md) 63:173–184. https://doi.org/10.1002/hep.28251 CrossRef

Suzuki T, Motohashi H, Yamamoto M (2013) Toward clinical application of the Keap1-Nrf2 pathway. Trends Pharmacol Sci 34:340–346. https://doi.org/10.1016/j.tips.2013.04.005 CrossRefPubMed

Taira N, Nihira K, Yamaguchi T, Miki Y, Yoshida K (2007) DYRK2 is targeted to the nucleus and controls p53 via Ser46 phosphorylation in the apoptotic response to. DNA Damage Mol Cell 25:725–738. https://doi.org/10.1016/j.molcel.2007.02.007 CrossRefPubMed

Tonnus W, Linkermann A (2016) “Death is my Heir"—ferroptosis connects cancer pharmacogenomics and ischemia-reperfusion injury. Cell Chem Biol 23:202–203. https://doi.org/10.1016/j.chembiol.2016.02.005 CrossRefPubMed

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108. https://doi.org/10.3322/caac.21262 CrossRefPubMed

Wang XJ et al (2008) Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs the dark side of Nrf2. Carcinogenesis 29:1235–1243. https://doi.org/10.1093/carcin/bgn095 CrossRefPubMedPubMedCentral

Wang D, Peng Y, Xie Y, Zhou B, Sun X, Kang R, Tang D (2016) Antiferroptotic activity of non-oxidative dopamine. Biochem Biophys Res Commun 480:602–607. https://doi.org/10.1016/j.bbrc.2016.10.099 CrossRefPubMed

Woo SM et al (2018) Corosolic acid induces non-apoptotic cell death through generation of lipid reactive oxygen species production in human renal carcinoma caki. Cells 19 https://doi.org/10.3390/ijms19051309 CrossRefPubMedCentral

Xie Y et al (2016) Identification of baicalein as a ferroptosis inhibitor by natural product library screening. Biochem Biophys Res Commun 473:775–780. https://doi.org/10.1016/j.bbrc.2016.03.052 CrossRefPubMed

Xie Y et al (2017) The Tumor Suppressor p53 Limits Ferroptosis by Blocking DPP4. Activity Cell Rep 20:1692–1704. https://doi.org/10.1016/j.celrep.2017.07.055 CrossRefPubMed

Yamaguchi Y, Kasukabe T, Kumakura S (2018) Piperlongumine rapidly induces the death of human pancreatic cancer cells mainly through the induction of ferroptosis. Int J Oncol 52:1011–1022. https://doi.org/10.3892/ijo.2018.4259 CrossRefPubMed

Yang WS et al (2014) Regulation of ferroptotic cancer cell death by GPX. 4 Cell 156:317–331. https://doi.org/10.1016/j.cell.2013.12.010 CrossRef

Yuan H, Li X, Zhang X, Kang R, Tang D (2016) CISD1 inhibits ferroptosis by protection against mitochondrial lipid peroxidation. Biochem Biophys Res Commun 478:838–844. https://doi.org/10.1016/j.bbrc.2016.08.034 CrossRefPubMed

Zhu S, Zhang Q, Sun X, Zeh HJ 3rd, Lotze MT, Kang R, Tang D (2017) HSPA5 regulates ferroptotic cell death in cancer cells. Cancer Res 77:2064–2077. https://doi.org/10.1158/0008-5472.can-16-1979 CrossRefPubMedPubMedCentral

Titel: Role of ferroptosis in hepatocellular carcinoma
verfasst von: Jianhua Nie
Binlin Lin
Meng Zhou
Li Wu
Tongsen Zheng
Publikationsdatum: 22.08.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 12/2018
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-018-2740-3

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Role of ferroptosis in hepatocellular carcinoma

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2018

Progress in gene therapy using oncolytic vaccinia virus as vectors

Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings

Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer

Analysis of prognostic factors of more/equal to10 years of survival for liver cancer patients after liver transplantation

Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancer

MiRNAs and their interplay with PI3K/AKT/mTOR pathway in ovarian cancer cells: a potential role in platinum resistance

Neu im Fachgebiet Onkologie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

Update Onkologie